Boston Medical Center

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Status: Recruiting

Location: "Beth Israel Deaconess Medical Center ", Allegheny-Singer Research Institution, Boston Medical Center, Brigham and Women's Hospital, Cedars-Sinai Medical Center, Lehigh Valley Health Network, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, University of Kansas Medical Center, University of Kentucky, University of Michigan, University of North Carolina Chapel Hill, University of Texas Southwestern, University of Utah

Conditions: "Beth Israel Deaconess Medical Center ", Allegheny-Singer Research Institution, Boston Medical Center, Brigham and Women's Hospital, Cedars-Sinai Medical Center, Lehigh Valley Health Network, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, University of Kansas Medical Center, University of Kentucky, University of Michigan, University of North Carolina Chapel Hill, University of Texas Southwestern, University of Utah

City/State:

Los Angeles, California

Los Angeles, California

Kansas City, Kansas

Lexington, Kentucky

Boston, Massachusetts

Ann Arbor, Michigan

New York, New York

Chapel Hill, North Carolina

Bethlehem, Pennsylvania

Pittsburgh, Pennsylvania

Dallas, Texas

Houston, Texas

Salt Lake City, Utah

Contact Information:

Kiranbir Josan, MD

Eric Yang, MD

Charles Porter, MD

Amit Arbune, MD

Daniel Zlotoff, MD, PhD 617-726-2000 [email protected]

Aarti Asnani or Abul Aritizia, MD

Omar Siddiqi

Anju Nohria, MD [email protected]

Salim Hayek, MD [email protected]

Dipti Gupta, MD

Brian Jensen, MD

Nicholas Trask

Valentyna Ivanova

Saketh Nadimpalli [email protected]

Nicolas Palaskas [email protected]

Anees Daud, MD

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

Read more
Click to access the login or register cheese
Contact Us

Contact Us

(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]

Social Media

Donations

Help Us End Suffering and Sudden Death from Myocarditis!

Donate to the Myocarditis Foundation Today!